Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients

Transplantation

Volumn 76, Issue 8, 2003, Pages 1233-1235

  Thervet, Eric ^a,b   Anglicheau, Dany ^a,b   King, Barry ^c   Schlageter, Marie Hélène ^b   Cassinat, Bruno ^b   Beaune, Philippe ^a   Legendre, Christophe ^b   Daly, Ann K ^c  

^a INSERM   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYTOCHROME P450 3A5; GENOMIC DNA; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS;

ADULT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; ENZYME ACTIVITY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PRIORITY JOURNAL;

ADULT; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; OSMOLAR CONCENTRATION; POLYMORPHISM, GENETIC; PREDICTIVE VALUE OF TESTS; TACROLIMUS;

EID: 0242332169     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000090753.99170.89     Document Type: Article

References (10)

1. Nebert DW, Gonzalez FJ. P450 genes: structure, evolution, and regulation. Annu Rev Biochem 1987; 56: 945.
2. Rendic S, Di Carlo FJ. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 1997; 29(1-2): 413.
3. Cholerton S, Daly AK, Idle JR. The role of individual human cytochromes P450 in drug metabolism and clinical response. Trends Pharmacol Sci 1992; 13(12): 434.
4. Watkins PB. Cyclosporine and liver transplantation: will the midazolam test make blood level monitoring obsolete? Hepatology 1995; 22(3): 994.
5. Finta C, Zaphiropoulos PG. The human cytochrome P450 3A locus: gene evolution by capture of downstream exons. Gene 2000; 260(1-2): 13.
6. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27(4): 383.
7. King BP, Leathart JBS, Mutch E, et al. CYP3A5 phenotype-genotype correlations in a British population. Br J Clin Pharmacol 2003; 55: 625.
8. Macphee IA, Fredericks S, Tai T, et al. Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. Transplantation 2002; 74(11): 1486.
9. Saeki T, Ueda K, Tanigawara Y, et al. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 1993; 268(9): 6077.
10. Kim RB. Pharmacogenetics of CYP enzymes and drug transporters: remarkable recent advances. Adv Drug Deliv Rev 2002; 54(10): 1241.